1233477-83-2

Upstream product

• 955929-58-5 4-cyano-2,6-dimethylphenyl trifluoromethanesulfonate 
• 1233244-42-2 4-allyl-3,5-dimethylbenzonitrile 
• 4198-90-7 3,5-dimethyl-4-hydroxybenzonitrile 

Downstream Products

• 1350824-94-0 3-(4-allyl-3,5-dimethylphenyl)-5-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadiazole 
• 1350824-95-1 2-(2,6-dimethyl-4-(5-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetaldehyde 
• 1350824-26-8 3-{2,6-dimethyl-4-[5-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-1,2,4-oxadiazol-3-yl]phenyl}propane-1,2-diol 

Relevant academic research and scientific papers

PYRAZOLE DERIVATIVES AS S1P1 AGONISTS

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

New pyrazole derivatives

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

New oxadiazole derivatives

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or N-oxide thereof: and its use in the treatment of diseases which are susceptible to improvement by sphingosine-1-phosphate (S1P1) receptor agonists.

NEW OXADIAZOLE DERIVATIVES

The present invention relates to an oxadiazole derivative of formula (I)1 or a pharmaceutically acceptable salt or N-oxide thereof: wherein, R1 represents a hydrogen atom, a C1-2 alkyl group or a C3-4 cycloalkyl-C1-2